Agarwal S, Joyner K A, Swaim M W
School of Medicine, Clinical Coagulation Laboratory, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Am J Gastroenterol. 2000 Nov;95(11):3218-24. doi: 10.1111/j.1572-0241.2000.03299.x.
Advanced liver disease is associated with both exaggerated fibrinolysis and with ascites. This study was undertaken to determine whether fibrinolytic activity exists in the ascites fluid of patients with liver disease and to see whether such activity is associated with evidence of plasma fibrinolysis.
Both the ascites fluid and plasma from 15 patients with cirrhotic ascites (group A) were evaluated for markers of fibrinolysis: fragment D-dimer, plasminogen, fibrinogen, and fibrin split products. In addition, the euglobulin lysis time, a test highly specific for fibrinolysis, was evaluated in the ascites fluid samples. As a control group, the plasma from 15 cirrhotic patients without ascites (group B) was evaluated for markers of fibrinolysis.
In group A, elevated fragment D-dimer and fibrin split products were uniformly found in ascites fluid in concentrations that would be considered pathologically elevated if in plasma. Ascites fluid was also depleted, compared with plasma, of both plasminogen and fibrinogen. These results, along with the short euglobulin lysis time in 83% of the patients, suggest that increased fibrinolytic activity is present in ascites fluid. In 93% of these patients, plasma D-dimer was elevated. The mean plasma plasminogen was also low in these patients. In group B, only 33% of patients had elevated plasma D-dimer.
Ascites fluid has fibrinolytic activity. Because ascites fluid reenters the systemic circulation via the thoracic duct, via a natural peritoneovenous shunt, ascites fluid warrants serious consideration as a pathological fluid that contributes to the systemic fibrinolytic state found in the majority of our patients with ascites.
晚期肝病与纤维蛋白溶解亢进及腹水均有关联。本研究旨在确定肝病患者腹水中是否存在纤维蛋白溶解活性,并观察这种活性是否与血浆纤维蛋白溶解的证据相关。
对15例肝硬化腹水患者(A组)的腹水和血浆进行纤维蛋白溶解标志物评估:D-二聚体片段、纤溶酶原、纤维蛋白原和纤维蛋白降解产物。此外,还对腹水样本进行了优球蛋白溶解时间评估,这是一种对纤维蛋白溶解具有高度特异性的检测。作为对照组,对15例无腹水的肝硬化患者(B组)的血浆进行纤维蛋白溶解标志物评估。
在A组中,腹水中均发现D-二聚体片段和纤维蛋白降解产物升高,其浓度若在血浆中则会被视为病理性升高。与血浆相比,腹水中的纤溶酶原和纤维蛋白原也减少。这些结果,连同83%的患者优球蛋白溶解时间缩短,提示腹水中存在增强的纤维蛋白溶解活性。在这些患者中,93%的患者血浆D-二聚体升高。这些患者的血浆纤溶酶原平均水平也较低。在B组中,只有33%的患者血浆D-二聚体升高。
腹水具有纤维蛋白溶解活性。由于腹水可通过胸导管、经自然的腹膜静脉分流重新进入体循环,腹水作为一种导致我们大多数腹水患者出现全身纤维蛋白溶解状态的病理性液体,值得认真考虑。